Saturday 17 October 2026
Export TLSI’s income statement to Excel — free account
TriSalus Life Sciences, Inc.
TLSI Healthcare Medical Devices
TriSalus Life Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $45.2 million, up 53.4% from fiscal 2024. In the quarter to June 2026, revenue grew 1.73%, EPS grew 40.7%, free cash flow fell 41.3% and total debt rose 2.45%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
3.63
0.27
−6.92%
Follow TLSI
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
5.88 | 4.59 | 5.86 | 4.98 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(26.19) | (31.81) | (106.49) | (53.98) | |
P/B ratio |
40.50 | 16.10 | 0.00 | 0.00 | |
Price to Tangible BV |
48.79 | 17.63 | 0.00 | 0.00 | |
EV/Sales |
5.60 | 4.08 | 6.14 | 5.24 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(11.06) | (9.15) | (15.40) | (9.92) | |
EV/FCF |
(10.52) | (8.71) | (14.16) | (9.23) | |
Quick Ratio |
4.72 | 5.24 | 2.35 | 2.54 | |
Current Ratio |
5.35 | 5.78 | 2.80 | 3.05 | |
Net Debt/EBITDA |
1.42 | 2.94 | (4.40) | (1.17) | |
Debt/Assets |
52.95% | 46.60% | 93.53% | 89.86% | |
Debt/Equity |
5.05 | 2.58 | (0.98) | (1.23) | |
Asset Turnover |
0.87 | 0.90 | 1.52 | 1.26 | |
Operating CF/Net income |
1.10 | (4.21) | 0.30 | 0.09 | |
Capex/Depreciation |
(0.17) | (0.33) | (0.10) | (0.40) | |
Interest Coverage |
(6.59) | (5.86) | (2.25) | (6.17) | |
Research and Development Expense of Revenue |
27.50% | 36.14% | 23.46% | 44.75% | |
Selling, General and Administrative Expense of Revenue |
145.31% | 144.56% | 87.97% | 116.70% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
22.93% | 27.78% | 16.64% | 29.59% | |
Graham Net Nets |
0.01 | 0.05 | (0.14) | (0.15) | |
Graham Number |
0.00 | 0.00 | 6.07 | 5.31 | |
Earnings Yield |
(28.57%) | (35.25%) | (26.22%) | (43.44%) | |
Free Cash Flow Yield |
(9.04%) | (10.18%) | (7.40%) | (11.40%) | |
Revenue per Share |
0.20 | 0.17 | 0.35 | 0.27 | |
Operating CF per Share |
(0.17) | (0.13) | (0.07) | (0.09) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.18) | (0.13) | (0.07) | (0.09) | |
Cash per Share |
0.79 | 1.10 | 0.54 | 0.53 | |
Shareholders Equity per Share |
0.11 | 0.25 | (0.89) | (0.62) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.11 | 0.25 | (0.89) | (0.62) | |
Free Cash Flow |
(10.21) | (6.62) | (2.52) | (3.88) | |
Working Capital |
48.57 | 56.35 | 20.75 | 22.42 | |
Capital Expenditures |
(0.08) | (0.14) | (0.04) | (0.18) | |
Net Current Asset Value |
3.85 | 9.97 | (36.95) | (29.86) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.02 | 0.00 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
6.02 | 5.33 | 5.82 | 4.96 | |
Average Payables |
2.83 | 3.52 | 2.64 | 2.62 | |
Average Inventory |
4.01 | 3.97 | 3.56 | 3.64 | |
Average Assets |
51.88 | 49.80 | 29.65 | 31.97 | |
Average Common Equity |
(6.44) | (10.78) | (29.88) | (23.58) |
Columns are period end dates